Cardiol Sees First Patient Enrolled Under Phase III MAVERIC Clinical Trial
Cardiol Therapeutics (TSX: CRDL) has reached a major milestone with the announcement that the first patients have been enrolled into a phase III clinical trial for its lead drug candidate, CardiolRx™.
Read more